Recombinant Human soluble Fas Receptor/TNFRSF6
Fas and Fas Ligand (FasL) belong to the TNF superfamily and are type I and type II transmembrane proteins, respectively. Binding of FasL to Fas triggers apoptosis in Fas-bearing cells. The mechanism of apoptosis involves recruitment of pro-caspase 8 through an adaptor molecule called FADD followed by processing of the pro-enzyme to active forms. These active caspases then cleave various cellular substrates leading to the eventual cell death. sFasR is capable of inhibiting FasL-induced apoptosis by acting as a decoy receptor that serves as a sink for FasL.
Reference
1. Zhang W, Ramdas L, Shen W, et al. 2003. Cancer Biol Ther, 2: 572-8
2. Takubo T, Kumura T, Nishiki S, et al. 2000. Acta Haematol, 103: 165-7
3. Lautrette C, Loum-Ribot E, Petit D, et al. 2006. Apoptosis, 11: 1195-204
4. Kovacic N, Grcevic D, Katavic V, et al. 2010. Lab Invest, 90: 402-13
5. Kaufmann T, Strasser A, Jost PJ. 2012. Cell Death Differ, 19: 42-50.
| Gene ID | 355 |
| Accession # | P25445 |
| Alternate Names | TNFRSF6, CD95, Apo I, Fas Antigen |
| Source | Escherichia coli. |
| M.Wt | Approximately 17.6 kDa, a single non-glycosylated polypeptide chain containing 157 amino acids. |
| AA Sequence | RLSSKSVNAQ VTDINSKGLE LRKTVTTVET QNLEGLHHDG QFCHKPCPPG ERKARDCTVN GDEPDCVPCQ EGKEYTDKAH FSSKCRRCRL CDEGHGLEVE INCTRTQNTK CRCKPNFFCN STVCEHCDPC TKCEHGIIKE CTLTSNTKCK EEGSRSN |
| Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the cytotoxicity of Jurkat cells is between 10-15 μg/ml in the presence of 2 ng/ml of rHuFas Ligand. |
| Shipping Condition | Gel pack. |
| Handling | Centrifuge the vial prior to opening. |
| Usage | For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 95 % by SDS-PAGE and HPLC analyses.
- Datasheet
Endotoxin: Less than 1 EU/μg of rHusFasR/TNFRSF6 as determined by LAL method.